Reports Q3 revenue $116.2M, consensus $113.5M. “Axonics (AXNX) continued to execute at a high level in the third quarter, generating revenue growth of 25% year over year,” said Raymond W. Cohen, chief executive officer. “Revenue growth for both sacral neuromodulation and Bulkamid(R) was driven by higher utilization at existing customers and the onboarding of new accounts.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXNX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue